ProQR Therapeutics N.V. (PRQR) |
|
1.6848 -0.07 (-4%)
|
06-09 13:35 |
|
Open: |
1.74 |
Pre. Close: |
1.755 |
|
High:
|
1.755 |
Low:
|
1.66 |
|
Volume:
|
420,114 |
Market Cap:
|
143(M) |
|
|
|
Technical analysis |
as of: 2023-06-09 1:17:05 PM |
|
Short-term rate:
|
 |
| Stoxline posted a SELL today, same as yesterday. Downward movement continues. |
|
Mid-term rate:
|
 |
| Target: |
Six months: 2.31 One year: 2.58 |
| Support: |
Support1: 1.62 Support2: 1.34 |
| Resistance: |
Resistance1: 1.98 Resistance2: 2.21 |
| Pivot: |
1.79 |
| Moving Average: |
MA(5): 1.77 MA(20): 1.8
MA(100): 2.52 MA(250): 1.72  |
| MACD: |
MACD(12,26): -0.1 Signal(9): -0.2 |
| Stochastic oscillator: |
%K(14,3): 32.1 %D(3): 44.2 |
| RSI: |
RSI(14): 36.6 |
| 52-week: |
High: 3.84 Low: 0.68 |
| Average Vol(K): |
3-Month: 801 (K) 10-Days: 329 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ PRQR ] has closed above bottom band by 16.5%. Bollinger Bands are 61.1% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 13 bars. This is a sign that the market may be about to initiate a new trend. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
1.78 - 1.79 |
1.79 - 1.8 |
|
Low:
|
1.69 - 1.7 |
1.7 - 1.71 |
|
Close:
|
1.74 - 1.76 |
1.76 - 1.77 |
|
Company Description |
|
ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It primarily develops sepofarsen that is in phase II/III clinical trial illuminate trial for treating leber congenital amaurosis 10 disease; and ultevursen, which is in phase II/III clinical trial to treat USH2A-mediated retinitis pigmentosa and usher syndrome. The company also engages in the developing of Axiomer RNA base-editing platform technology. It has a license agreement with Radboud University Medical Center, Inserm Transfert SA, Ionis Pharmaceuticals, Inc., and Leiden University Medical Center, as well as license and research collaboration with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. ProQR Therapeutics N.V. was incorporated in 2012 and is headquartered in Leiden, the Netherlands. |
Headline News |
Sun, 28 May 2023
M28 Capital Management LP Grows Stake in ProQR Therapeutics ... - MarketBeat
Sun, 21 May 2023
ProQR Therapeutics NV: Developing RNA Therapies for Rare ... - Best Stocks
Thu, 18 May 2023
ProQR Therapeutics N.V. (NASDAQ:PRQR) Could Be Less Than A Year Away From Profitability - Yahoo Finance
Wed, 17 May 2023
Cantor Fitzgerald Maintains ProQR Therapeutics N.V (PRQR ... - Nasdaq
Tue, 16 May 2023
ProQR: Q1 Earnings Snapshot - Danbury News Times
Tue, 16 May 2023
Is ProQR Therapeutics NV (PRQR) a Good Choice in Biotechnology Tuesday? - InvestorsObserver
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Neutral |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Outperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
0 (M) |
| Shares Float |
81 (M) |
|
% Held by Insiders
|
6.281e+007 (%) |
|
% Held by Institutions
|
19.2 (%) |
|
Shares Short
|
2,580 (K) |
|
Shares Short P.Month
|
0 (K) |
Stock Financials |
|
EPS
|
-5.63e+007 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
0 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
-1 |
|
Return on Assets (ttm)
|
336.9 |
|
Return on Equity (ttm)
|
-20.5 |
|
Qtrly Rev. Growth
|
4.27e+006 |
|
Gross Profit (p.s.)
|
-1085 |
|
Sales Per Share
|
-1876 |
|
EBITDA (p.s.)
|
1.2e+008 |
|
Qtrly Earnings Growth
|
-1 |
|
Operating Cash Flow
|
0 (M) |
|
Levered Free Cash Flow
|
-3 (M) |
Stock Valuations |
|
PE Ratio
|
-0.01 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
0 |
|
Price to Sales
|
-0.01 |
|
Price to Cash Flow
|
0.09 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
1.37e+006 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
